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Purpose: Uveal melanoma is the most common primary intraocular malignancy. 
Extrascleral extension (ESE) by this tumor is rare, but associated with an increased rate 
of orbital recurrence and an overall poor prognosis. Clinical studies show low rates when 
compared with histological studies. Due to the prognostic importance of ESE, we seek to 
compare our clinical, intraoperative, and histological detection rates. 
 
Design: A retrospective cross-sectional case series. 
 
Methods: A list of eyes enucleated for uveal melanoma was compiled from the 
admissions records of the London Ocular Oncology Service during the 28-month period 
between January 2010 and April 2012. The surgical and clinical notes of patients with 
histopathology reports positive for ESE were reviewed to determine when it was first 
diagnosed or suspected. The subsequent management of these cases is discussed. 
 
Results: 16 of 174 (9%) eyes had histologically proven ESE.  8 of 16 cases were detected 
preoperatively at clinical examination including the use of ocular ultrasound, 3 of 16 
were discovered intra-operatively, and 5 of 16, deemed microscopic ESE, were first 
detected on histological examination. 7 out of 7 (100%) of cases with anterior ESE were 
detected clinically by slit lamp biomicroscopy, while only 1 out of 9 (11%) of cases with 
posterior ESE were detected preoperatively with ultrasound.   
 
Conclusions: Slit lamp biomicroscopy is sensitive for detecting anterior ESE.  Most 
cases of posterior ESE are microscopic, but B-scan ocular ultrasound may also miss 
macroscopic posterior ESE. Orbital surgeons should be aware of the possibility of 
clinically undetected posterior ESE, and consider adjuvant orbital radiotherapy in cases 




     Uveal melanoma is the most common primary intraocular malignancy [1]. Mortality is 
typically due to liver failure secondary to metastatic disease. [2] Extrascleral extension 
(ESE) is rare, but has been associated with an increased rate of orbital recurrence, as well 
as an overall poor prognosis. [3,4] Other features correlated with early metastatic death 
include: advanced patient age, large tumor size, ciliary body involvement, epithelioid 
cellular morphology, periodic acid-Schiff (PAS) positive vascular mimicry patterns, 
increased nucleolar size, and loss of a copy of chromosome 3 (monosomy 3). [5-10] 
Several large studies show low rates of clinical versus histological detection.  Due to its 
prognostic importance, we seek to compare our clinical, intraoperative, and histological 




     Clinical cohort analysis was performed on all enucleations (primary and secondary) 
undertaken in the London Ocular Oncology Service following a diagnosis of uveal 
melanoma between January 2010 and April 2012. Histopathology reports documenting 
ESE were correlated with the histology. The surgical and clinical notes were obtained for 
these cases to determine if and when the ESE was detected preoperatively or 
intraoperatively. 
     All patients underwent complete clinical examination with slit lamp biomicroscopy, 
indirect ophthalmoscopy and transpupillary transillumination. B-scan ocular ultrasound 
(Acuson Sequoia 512 by Siemens) using the 14MHz probe was performed on all patients. 
MRI scans of the orbit were not requested unless the clinician was suspicious of ESE 
following ocular ultrasound. Tumor locations, sizes and pigmentation were recorded.  
Any treatments prior to enucleation and adjuvant therapies were also recorded. 
Histopathologic assessment was done with standard hematoxylin and eosin stain. 
Melanoma histopathologic cell type, mitotic figures and routes of ESE were recorded. In 
most of the cases cytogenetic analysis of chromosomes 3 and 8 was performed with 
Interphase fluorescence in situ hybridization (FISH) analysis following a punch biopsy of 
	 4	
the intraocular tumor (Abbott Molecular (Des Plaines, IL, U.S.A.) IGH/MYC, CEP8 tri-
color dual fusion probe, CEP3 (D3Z1)SpectrumOrange Probe, and CEP8 (D8Z2) 




     During the 28-month study period, a total of 174 patients with uveal melanoma 
underwent enucleation. Histopathology reported the presence of ESE in 16 of 174 (9%) 
of patients. Patients with ESE had a median age of 79.5 years (mean 74.5 ± 6.4, range 49-
88), of which 8 were male and 8 were female patients. There was no significant 
difference in age between the patients with anterior versus posterior ESE (p-value 0.227, 
Kruskal-Wallis).  Patient demographics and tumor features are presented in Tables 1 and 
2 for anterior and posterior ESE respectively.  
     Eight cases were diagnosed at preoperative clinical examination, 3 were discovered 
intraoperatively, and 5 were first detected on histopathologic examination.  The cell types 
of the tumors were: 10 spindle, 4 mixed, and 2 epithelioid.  More than half (9/16) of the 
tumors were medium sized according to the Collaborative Ocular Melanoma Study 
(COMS).  Of the 14 cases that had cytogenetic testing, 12 (86%) were found to have 
chromosomal abnormalities in chromosomes 3 and/or 8.  
     All patients with clinically or intraoperatively detected ESE received modified 
enucleation surgery with care to avoid manipulation of the tissues overlying the 
extraocular portion of the tumor. 10 patients had well-encapsulated or microscopic ESE.  
These patients did not receive any adjuvant treatment but were monitored in the Ocular 
Oncology Service. Adjuvant external beam radiotherapy (EBRT), 50 Gy in 20 fractions, 
was administered to the orbit of 6 patients who had non-encapsulated macroscopic ESE.   
 
Anterior ESE 
 					Seven	 patients	 had	 anterior	 ESE.	 These	 patients	 had	 a	median	 age	 of	 84	 years	(mean	74.6,	range	49-88)	and	nearly	all	were	female	(6/7).	Six	out	of	7	patients	had	not	received	prior	radiation	treatment.	The	melanomas	were	predominantly	located	
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in	the	ciliochoroidal	area	(5/7),	were	medium-sized	(5/7),	dome-shaped	(4/7)	and	melanotic	(6/7).	Regardless	of	the	size	of	the	ESE,	all	anterior	cases	were	clinically	detected	by	slit	 lamp	biomicroscopy.	Clinical	presentation	of	 the	extension	ranged	from	transscleral	discoloration	to	a	frank	sizeable	subconjunctival	nodule	(Table	1A	–	Notes).	Histopathologically,	4/7	were	spindle	cell	type	with	2	cases	of	mixed	type	and	only	one	case	with	epithelioid	morphology.	Cytogenetic	analysis	 indicated	 the	presence	 of	 monosomy	 of	 chromosome	 3	 in	 4/7	 cases	 and	 abnormalities	 in	chromosome	8	in	6/7	cases.		
Interestingly, two patients developed anterior ESE following previous transcleral 
manipulation at the site of the extension (fine needle aspiration biopsy site, and 
trabeculectomy scleral flap). The other route of the ESE for these ciliochoroidal 
melanomas was also determined to be the aqueous drainage channels or adjacent to 




     Nine patients had posterior ESE. These patients had a median age of 79 years (mean 
74.4, range 56-86) and most of the patients (7/9) were male. Seven out of 9 patients had 
not received prior treatment. The intraocular tumors were predominantly isolated to the 
posterior pole (5/9), were large (5/9) or medium-sized (4/9), collar-stud shaped (6/9), and 
were all melanotic. B-scan ultrasound only detected the ESE in the case with the largest 
posterior extension (a 6 mm nodule, see Table 1B – Notes).  The other cases of 
macroscopic and microscopic posterior ESE were first discovered intraoperatively (3 
during enucleation), or following microscopic examination (5).  Histopathologically, 6/9 
were spindle type with 2 cases of mixed type and only one case with epithelioid 
morphology. Cytogenetic analysis in this group was available for 6 cases. Chromosome 3 
abnormalities were detected in 5/6 cases and chromosome 8 abnormalities in 5/6 cases.  
     The routes of the extension were posterior ciliary artery or nerve emissary canals in 
4/9 cases, the vortex veins in 3/9 cases, the optic nerve in 1/9 case, and transcleral 





     In this study, the incidence and detection of ESE in eyes enucleated for uveal 
melanoma were assessed retrospectively in a large series from a single tertiary referral 
Ocular Oncology center. The overall incidence of histopathologically confirmed 
extrascleral extension in our series was 9%. This is in accordance with previous studies 
noting extrascleral extension in 13% of choroidal melanomas [4,11] though older series 
have reported percentages as high as 29% [4].  The ages of the patients with anterior vs. 
posterior ESE were comparable. 
   
PRIOR TREATMENTS 
 
     Enucleation was the primary treatment modality for 13 patients, but secondary in 3 
patients after failed ruthenium plaque brachytherapy.  It is unlikely that the brachytherapy 
facilitated ESE, as the sclera has been shown to be able to withstand more than 1000 Gy 
before induction of scleral atrophy/thinning. [14] All of the patients who received prior 
brachytherapy had a dose of less than 1000 Gy to the sclera. The two patients with full 
thickness direct transcleral extension had previous transcleral procedures overlying their 
intraocular tumors (Patient #6 required two trans-scleral fine needle aspiration (FNA) 
biopsies to confirm the diagnosis, Patient #7 had a previous trabeculectomy).  Tumor 
seeding along the FNA biopsy needle track is a known and well-described risk of the 
procedure. [15] Direct transcleral tumor extension after glaucoma filtration surgery has 
also been described. [16] 
 
MELANOMA SIZE, HISTOPATHOLOGY TYPE AND CYTOGENETICS 
 
     Although previously published studies [4,11] found ESE to be associated with 
increased tumor size and epithelioid morphology, we did not have an overabundance of 
tumors meeting the COMS criteria for large tumors [2] and most of our cases were 
spindle cell tumors (10/16).  
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     Importantly, more than 80% of melanomas showing ESE harbored high-risk 
cytogenetic features with abnormalities in chromosomes 3 and or 8 known to be 
associated with a poor survival prognosis.  Researchers in Holland have also reported 
monosomy of chromosome 3 and gains of chromosome 8q in patients with ESE [12]. In 
our study the intraocular component of the tumor was tested for cytogenetic analysis, 
since biopsy from extraocular tumor has not been shown to be representative of the 
underlying cytogenetic changes with respect to chromosome 1p, 3, 6, and 8q 
abnormalities [13]  
 
ROUTES OF EXTRASCLERAL EXTENSION 
 
     Most of the ESE occurred via aqueous outflow vessels, or along emissary canals 
carrying posterior ciliary nerves, arteries, and vortex veins. Complete direct extension 
through the sclera was uncommon in our series as in other studies [11]. Similarly, despite 
the fact that many uveal melanomas are juxtapapillary, direct invasion of the optic nerve 




     Our clinical detection rate of ESE among cases of proven uveal melanoma was 5% 
versus the 9% histological detection rate.  This compares favorably with recent large 
studies, which have found clinical detection rates of 3% versus 10-15% histologically. 
[7,8,14,19-20]  The clinical detection of ESE was largely related to an anterior or 
posterior location.  Clinical detection of anterior ESE was excellent regardless of the 
extent, with all 7 of these cases noted on slit lamp biomicroscopy either as a fixed 
subconjunctival nodule or flat subconjunctival pigment overlying the intraocular 
melanoma (Figure Top left, Top right).  Murray et al published on the value of ocular 
ultrasound in detecting ESE, with ultrasound being superior to MRI scanning (22). In the 
current study we found B-scan ocular ultrasound detected 1 out of 4 cases with posterior 
macroscopic ESE. The case detected using ultrasound was a 6mm nodular extension 
(Figure Middle left, Middle right).  The 3 cases missed using B-scan ocular ultrasound 
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were all small nodular extensions of less than 2mm in thickness. The route of ESE for all 
of these 3 cases was via the emissary channel containing the posterior ciliary artery or 
nerve. Extrascleral spread of melanoma into the orbital fat is detected on the B-Scan 
image as a region of lower echogenicity than the surrounding strongly scattering orbital 
fat. Tumor appears as grey spots of varying brightness surrounded by and outlined by 
the brighter white spots of the orbital fat.  Small extrascleral extensions at muscle 
insertions can be difficult to detect.  Retrobulbar tissues that can obscure B-scan 
ultrasound images may also impede direct intraoperative visualization of episcleral 
pigment and macroscopic nodules (Figure Bottom left, Bottom right) from orbital 
surgeons.  Post surgical cystic spaces at plaque sites may lead to false positives.  
Conversely, if there is tumor spread into the optic nerve then tumor echoes are detected 
within the normally echolucent nerve complex and the dark area of the nerve complex 
outlines the grey of the tumor. In the latter situation, blood flow imaging using 
Ultrasound Color Flow Mapping (CFM) has a particularly useful role. Blood vessels 
detected within the nerve complex, other than normal retinal artery and vein, represent 




     If ESE is suspected enucleation approaches should be modified with care to avoid 
handling the tissues overlying the intraocular tumor. The presence of microscopic ESE 
did not change our overall management; however non-encapsulated macroscopic ESE 
was treated with EBRT. This has been the longstanding management of ESE in uveal 
melanoma in London since Hykin et al. reported a low orbital recurrence rate of only 6% 
in these high-risk cases.  
As of March 2017, none of the patients who received EBRT and none of the patients 
monitored with microscopic ESE have had an orbital recurrence.  Though there is 
currently no long-term data to support improved mortality, we believe offering adjuvant 
orbital radiotherapy in cases of non-encapsulated macroscopic ESE is a prudent choice to 
prevent orbital recurrences. [3] Paul Finger et al. have also reported success in preventing 
orbital recurrence with high-dose-rate (HDR) orbital brachytherapy. [21]  
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     In conclusion, while detailed examination using slit lamp biomicroscopy is very 
sensitive for detection of anterior ESE, small posterior ESE may be missed with B-scan 
ultrasound. Most microscopic ESE not seen intraoperatively does not require adjuvant 
radiotherapy to the socket, and thus does not change overall patient management. The 
surgical technique should be modified when anterior or posterior ESE is suspected. As in 
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Figure Caption: Presentation of anterior ESE on slit lamp exam varied between fixed 
subconjunctival nodules with dilated and tortuous sentinel vessels (Upper left, case #3) 
and flat subconjunctival pigment (Upper right, case #4). Middle left shows B-scan 
ultrasound and, Middle right demostrates corresponding Hematoxylin and Eosin stained 
slide showing a 6mm posterior extrascleral nodule (case #11, ‘T’ denotes tumor, ‘S’ the 
sclera, and ‘ON’ the optic nerve). Bottom left shows tumor cells exiting the eye via the 
vortex vein (‘VV’), noted as episcleral pigment intraoperatively (case #12), Bottom right 
shows 2mm extrascleral nodule hidden intraoperatively by the inferior oblique (‘IO’) 









AJCC	Staging	 Cytogenetics		 Pigment	 Tumor	location	 Tumor	shape	 ESE	detection	 Route	 Previous	
therapy	 Notes	
1	 85	 F	 Spindle	cell	 Large	 Stage	IIIB	(T3dNxM0)	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Ciliochoroidal	 Dome	shaped	 Clinical	 Aqueous	Drainage	channels	 No	 3mm	focus	2	 88	 F	 Spindle	cell	 Large	 Stage	IIIB	(T3dNxM0)	 Monosomy	3/	Gain	of	8	 Melanotic	 Ciliochoroidal	 Bilobed	 Clinical	 Not	determined	 No	 4.5mm	nodule	
3	 84	 F	 Mixed	 Medium	 Stage	IV	(T4eNxM1c)	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Ciliochoroidal	 Dome	shaped	 Clinical	 Aqueous	Drainage	channels	 No	 14x10mm	subconjunctival	nodule,	liver	metastasis	at	initial	diagnosis	
4		 84	 M	 Epithelioid	 Medium	 Stage	IIIa	(T2cNxM0)	 Trisomy	3/	Gain	of	8/8q	 Melanotic	 Choroidal	nasal	 Dome	shaped	 Clinical	 Ciliary	artery,nerve	 No	 Transcleral	discoloration	with	tumor	cells	
5		 64	 F	 Spindle	cell	 Medium	 Stage	IIIA	(T2dNxM0)	 Disomy	3/	Disomy	8	 Amelanotic	 Ciliochoroidal	 Collar	stud	 Clinical	 Transcleral	 No	 	
6		 49	 F	 Mixed	 Medium	 Stage	IIIA	(T2dNxM0)	 Disomy	3/	Gain	of	8q24	 Melanotic	 Anterior	 Bilobed	 Clinical	 Transcleral	 Brachytherapy	+	(FNA	x2)	 	




sex	 Histology	type	 Tumor	size	(COMS	classification)	 AJCC	Staging	 Cytogenetics		 Pigment	 Tumor	location	 Tumor	shape	 ESE	detection	 Route	 Previous	therapy	 Notes	
1	 63	 M	 Spindle	cell	 Large	 Stage	IIIA	(T3cNxM0)	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Superior	 Collar	stud	 Histopathologic	 Not	noted	 No	 2mm	extrascleral	deposit	
2	 81	 M	 Mixed	 Large	 Stage	IIIB	(T3dNxM0)	 Not	done	 Melanotic	 Ciliochoroidal	to	posterior	 Collar	stud	 Histopathologic	 Posterior	ciliary	nerve,	artery	
Brachytherapy	 <1mm	encapsulated	nodule	
3	 78	 M	 Spindle	cell	 Medium	 Stage	IIIA	(T2cNxM0)	 Not	done	 Melanotic	 Posterior	 Dome	shaped	 Histopathologic		 Posterior	ciliary	artery	 Brachytherapy	x	2	 2mm	encapsulated	nodule	
4	 84	 F	 Spindle	cell	 Large	 Stage	IIIC	(T4eNxM0)	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Superior	 Multilobed	 Clinical	 Posterior	ciliary	nerve,	artery,	transcleral	
No	 6mm	nodule	
5	 79	 F	 Spindle	cell	 Medium	 Stage	IIIA	(T2cNxM0)	 Disomy	3/	Disomy	8	 Melanotic	 Ciliochoroidal	 Collar	stud	 Intraoperative	 Vortex	vein	 No	 Cells	coating	3mm	of	external	sclera	6	 56	 M	 Spindle	cell	 Medium	 Stage	IIIA	(T2cNxM0)	 Monosomy	3/	Gain	8q	 Melanotic	 Inferior	 Collar	stud	 Histopathologic	 Vortex	vein	 No	 	
7	 63	 M	 Mixed	 Medium	 2/mm2	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Posterior	 Dome	shaped	 Intraoperative	 Vortex	vein	 No	 	
8	 86	 M	 Spindle	cell	 Large	 2/mm2	 Monosomy	3/	Gain	of	8/8q	 Melanotic	 Posterior	 Collar	stud	 Intraoperative	 Posterior	ciliary	nerve	 No	 2mm	nodule	
9	 80	 M	 Epithelioid	 Large	 1/10	high	powered	fields	 Not	done	 Melanotic	 Posterior	 Collar	stud	–	filling	most	of	the	globe		
Histopathologic		 Optic	nerve	 No	 Focal	infiltration	of	lamina	cribrosa			 	
